The Risk of <i>Clostridioides difficile</i> Recurrence after Initial Treatment with Vancomycin or Fidaxomicin Utilizing Cerner Health Facts

(1) Background: Fidaxomicin has been shown to significantly reduce <i>Clostridioides difficile</i> infection (CDI) recurrences rates in randomized, controlled trials. However, national data from the Veterans Affairs has called the real-world applicability of these findings into question. Therefore,...

Whakaahuatanga katoa

Ngā taipitopito rārangi puna kōrero

Ngā kaituhi matua:	Ronald G. Hall, Travis J. Cole, Chip Shaw, Carlos A. Alvarez
Hōputu:	Artigo
Reo:	Inglês
I whakaputaina:	MDPI AG 2022-02-01
Rangatū:	Antibiotics
Ngā marau:	fidaxomicin vancomycin <i>Clostridioides difficile</i> CDI recurrence
Urunga tuihono:	https://www.mdpi.com/2079-6382/11/3/295
Ngā Tūtohu:	Tāpirihia he Tūtohu Kāore He Tūtohu, Me noho koe te mea tuatahi ki te tūtohu i tēnei pūkete!